stockrowBiogen Inc.
BIIBHealthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. (BIIB) EBITDA
Biogen Inc.'s EBITDA for fiscal 2025 was $2.9B, down 6.89% from $3.2B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.3B. Over the past ten years it has ranged from $2.1B (fiscal 2023) to $7.7B (fiscal 2019); the current reading is higher than 18% of that period. Biogen Inc. ranks 13th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $2.9B | (6.89%) |
| FY2024 | $3.2B | 47.42% |
| FY2023 | $2.1B | (48.11%) |
| FY2022 | $4.1B | 4.14% |
| FY2021 | $4.0B | (28.10%) |
| FY2020 | $5.5B | (28.73%) |
| FY2019 | $7.7B | 18.11% |
| FY2018 | $6.5B | 1.75% |
| FY2017 | $6.4B | 10.15% |
| FY2016 | $5.8B | 6.25% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $566.7M | (3.92%) |
| Jun 2026 | $589.8M | (16.86%) |
| Mar 2026 | $709.4M | 67.55% |
| Dec 2025 | $423.4M | (50.49%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S compare | $27.2B |
| AZN AstraZeneca PLC compare | $21.2B |
| PFE Pfizer Inc. compare | $20.1B |
| AMGN Amgen Inc. compare | $17.2B |
| BMY Bristol Myers Squibb Company compare | $14.1B |
| GSK GSK PLC Sponsored ADR compare | $12.2B |
| SNY Sanofi compare | $11.1B |
| BIIB Biogen Inc. | $2.3B |
| GILD Gilead Sciences, Inc. compare | $451.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement